Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study von Shore, Neal D., Fizazi, Karim, Tammela, Teuvo L.J., Luz, Murilo, Salas, Manuel Philco, Ouellette, Paul, Lago, Sérgio, Bastos, Diogo Assed, Kenneth Jansz, G., Cárcano, Flavio Mavignier, Andrade, Lívia, Pliskin, Marc, Lazaretti, Nicolas, Arruda, Larissa, Ochoa, José Jaime Correa, Kuss, Iris, Kappeler, Christian, Sarapohja, Toni, Smith, Matthew

Volltext

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer von Fizazi, Karim, Shore, Neal, Tammela, Teuvo L, Ulys, Albertas, Vjaters, Egils, Polyakov, Sergey, Jievaltas, Mindaugas, Luz, Murilo, Alekseev, Boris, Kuss, Iris, Kappeler, Christian, Snapir, Amir, Sarapohja, Toni, Smith, Matthew R

Volltext

Analysis of the effect of crossover from placebo (PBO) to darolutamide (DARO) on overall survival (OS) benefit in the ARAMIS Trial von Shore, Neal D., Fizazi, Karim, Tammela, Teuvo, Luz, Murilo, Philco Salas, Manuel, Ouellette, Paul, Lago, Sergio, Bastos, Diogo Assed, Jansz, G. Kenneth, Carcano, Flavio Mavignier, Andrade, Livia, Pliskin, Marc, Lazaretti, Nicolas, De Arruda, Larissa, Correa, Jose Jaime, Petrenciuc, Oana, Kappeler, Christian, Sarapohja, Toni, Smith, Matthew Raymond

Volltext